Literature DB >> 3003746

A complete library of point substitution mutations in the glucocorticoid response element of mouse mammary tumor virus.

C A Hutchison, S K Nordeen, K Vogt, M H Edgell.   

Abstract

The glucocorticoid response element (GRE) of mouse mammary tumor virus (MMTV) was chemically synthesized as two complementary DNA strands bearing cohesive termini. During automated synthesis, random mutations were introduced into the DNA by "doping" each of the four nucleoside phosphoramidites (A, G, C, and T) with a low level of the other three. These preparations were annealed and cloned into an M13 phage vector to produce a library of GRE mutants. Mutations within the synthesized region were identified by sequencing phage isolates at random. All of the chemically distinct classes of transition and transversion mutations have been observed. Statistical considerations indicate that the library contains all of the possible 90 point substitution mutations within a 30-nucleotide mutagenic target. So far 88 of these substitutions have been isolated, 74 as single mutants. At least two of the three possible single mutants at each of the 30 positions have been identified.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3003746      PMCID: PMC322934          DOI: 10.1073/pnas.83.3.710

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  In vitro mutagenesis.

Authors:  M Smith
Journal:  Annu Rev Genet       Date:  1985       Impact factor: 16.830

2.  Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites.

Authors:  J A Wells; M Vasser; D B Powers
Journal:  Gene       Date:  1985       Impact factor: 3.688

3.  Directed semisynthetic point mutational analysis of an RNA polymerase III promoter.

Authors:  M H Murphy; F E Baralle
Journal:  Nucleic Acids Res       Date:  1983-11-25       Impact factor: 16.971

4.  Contacts between hormone receptor and DNA double helix within a glucocorticoid regulatory element of mouse mammary tumor virus.

Authors:  C Scheidereit; M Beato
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

5.  Functional analysis of the steroid hormone control region of mouse mammary tumor virus.

Authors:  F Lee; C V Hall; G M Ringold; D E Dobson; J Luh; P E Jacob
Journal:  Nucleic Acids Res       Date:  1984-05-25       Impact factor: 16.971

6.  Nucleotide sequencing of an apparent proviral copy of env mRNA defines determinants of expression of the mouse mammary tumor virus env gene.

Authors:  J E Majors; H E Varmus
Journal:  J Virol       Date:  1983-09       Impact factor: 5.103

7.  Hormonal response region in the mouse mammary tumor virus long terminal repeat can be dissociated from the proviral promoter and has enhancer properties.

Authors:  H Ponta; N Kennedy; P Skroch; N E Hynes; B Groner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

8.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors.

Authors:  C Yanisch-Perron; J Vieira; J Messing
Journal:  Gene       Date:  1985       Impact factor: 3.688

9.  Glucocorticoid regulation of mouse mammary tumor virus: identification of a short essential DNA region.

Authors:  E Buetti; H Diggelmann
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

10.  Mutagenesis of the three bases preceding the start codon of the beta-galactosidase mRNA and its effect on translation in Escherichia coli.

Authors:  A Hui; J Hayflick; K Dinkelspiel; H A de Boer
Journal:  EMBO J       Date:  1984-03       Impact factor: 11.598

View more
  48 in total

1.  Alterations in the hydrophilic segment of the maltose-binding protein (MBP) signal peptide that affect either export or translation of MBP.

Authors:  J W Puziss; R J Harvey; P J Bassford
Journal:  J Bacteriol       Date:  1992-10       Impact factor: 3.490

2.  Sequence-specific Rho-RNA interactions in transcription termination.

Authors:  James E Graham
Journal:  Nucleic Acids Res       Date:  2004-06-04       Impact factor: 16.971

3.  A method for introducing random single point deletions in specific DNA target sequences using oligonucleotides.

Authors:  S S Ner; T C Atkinson; M Smith
Journal:  Nucleic Acids Res       Date:  1989-06-12       Impact factor: 16.971

4.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases.

Authors:  D D Loeb; C A Hutchison; M H Edgell; W G Farmerie; R Swanstrom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  A ras effector domain mutant which is temperature sensitive for cellular transformation: interactions with GTPase-activating protein and NF-1.

Authors:  J E DeClue; J C Stone; R A Blanchard; A G Papageorge; P Martin; K Zhang; D R Lowy
Journal:  Mol Cell Biol       Date:  1991-06       Impact factor: 4.272

6.  Improving upon nature: active site remodeling produces highly efficient aldolase activity toward hydrophobic electrophilic substrates.

Authors:  Manoj Cheriyan; Eric J Toone; Carol A Fierke
Journal:  Biochemistry       Date:  2012-02-16       Impact factor: 3.162

7.  Mutant profiles of selectable genetic elements.

Authors:  H Wurst; F M Pohl
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

8.  A cluster of mutations in HLA-A2 alpha 2 helix abolishes peptide recognition by T cells.

Authors:  R J Moots; M Matsui; L Pazmany; A J McMichael; J A Frelinger
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

9.  Regulatory factor-X binding to mutant HLA-DRA promoter sequences.

Authors:  S L Hasegawa; J H Sloan; W Reith; B Mach; J M Boss
Journal:  Nucleic Acids Res       Date:  1991-03-25       Impact factor: 16.971

10.  Spo0A binds to a promoter used by sigma A RNA polymerase during sporulation in Bacillus subtilis.

Authors:  S Satola; P A Kirchman; C P Moran
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.